UNSPSC 51152060: Inaperisone hydrochloride

This classification denotes a muscle relaxant with the molecular formula C16H23NO.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 67D70I271P, chemically known as inaperisone hydrochloride, (+/-)-, but more generally known as inaperisone hydrochloride, which bears US NIH Compound Identifier 147524. European Medicines Agency schedules inaperisone hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08162MIG.

Most nations, for tariff purposes, schedule inaperisone hydrochloride under HS 29339990. SMILES: CCC1CCC(CC1)C(=O)C(C)CN2CCCC2.CL.

UNSPSC 51152060 Inaperisone hydrochloride is a Commodity code representing a single pharmaceutical product, but recent state and local opportunities tagged under this code show significant misalignment with the nominal scope. The Seminole County, Florida solicitation (IFB 60459723LAS) centers on procurement of naloxone and safe drug deactivation systems for community health initiatives, while the Texas Health and Human Services Commission RFI (HHS0017013) addresses direct-to-manufacturer prescription program capabilities and pharmacy benefit management strategy — neither involves inaperisone hydrochloride specifically. State and local governments appear to be using this code as a catch-all for pharmaceutical procurement and health-related drug products rather than for the specific muscle relaxant indicated by the code's name.

Geographic activity centers on Florida and Texas based on recent postings. Seminole County, a county-level issuing body, represents the primary concrete solicitation with a defined scope: 1,900 units of naloxone and 800 safe drug deactivation systems annually under an IFB with a response deadline of July 26, 2023, requiring quarterly deliveries to the Seminole County Community Health Building in Sanford. The Texas HHS Commission's April 3, 2026 RFI represents exploratory activity at the state level, gathering vendor capabilities for potential future direct-to-manufacturer pharmacy programs. Because the code shows little relevant activity aligned to its actual commodity definition, practitioners should verify whether this code applies to their offering or whether a broader pharmaceutical or health-product code better captures state and local buying patterns in this space.